HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and foreign trade services. We have established a "1+2+3+4=1" service system and can supply L-Tryptophan sourced directly from multiple well-known original manufacturers. As a foreign trader with independent R&D capabilities, HiSiaddi has collaborated with factories on multiple technology conversion projects. With precise insight into market demands, we have repeatedly resolved customized L-Tryptophan product requirements for clients. Below is a case of HiSiaddi addressing customized L-Tryptophan demands.
Please contact HiSiaddi customer service if you require more customized service solutions.
The client is PharmaMax, a top-tier high-end pharmaceutical enterprise based in Germany. It specializes in high-purity anti-depressant APIs, nutritional fortifiers for infant medical food, and high-purity amino acid infusion solutions. Its products are supplied to premium hospital pharmacies and medical food channels across Germany, Switzerland and Austria. The company strictly complies with six major standards: European Pharmacopoeia (EP), United States Pharmacopeia (USP), EU REACH, non-GMO, allergen-free and low endotoxin. Its customized L-Tryptophan requirements are as follows: purity ≥99.5%, single impurity ≤0.05%, endotoxin <0.1EU/mg, no peculiar fermentation odor, stable crystal form, and compatibility with low-temperature sterile injection production. This client targets mid-to-high-end markets with extremely stringent customized indicators and zero tolerance for trial errors.
In March 2026, the client launched R&D for a new generation of high-purity 5-hydroxytryptamine precursor drugs and required customized exclusive L-Tryptophan raw materials with core specifications as below:
1. Ultra-high purity: ≥99.5%, far exceeding the standard of conventional food grade (98.5%) and general pharmaceutical grade (99%);
2. Ultra-low impurity level: single impurities (including optical isomers and fermentation by-products) ≤0.05%, endotoxin <0.1EU/mg;
3. Special crystal form: α-type acicular crystals with good fluidity and high solubility in sterile water, suitable for low-temperature injectable production;
4. Customized packaging: sterile double-layer aluminum foil vacuum packaging filled with nitrogen, 5kg per bag, complying with EU sterile pharmaceutical packaging standards;
5. Exclusive traceability: full English batch traceability reports linked to fermentation strains, purification processes and test data to meet EP audit requirements.
The client previously contacted 3 domestic L-Tryptophan manufacturers, yet all cooperation attempts failed due to inability to meet purity and impurity limits, lack of crystal form customization capacity, substandard sterile packaging, and poor technical coordination. Conventional manufacturers only supply general powder with purity ranging from 98.5% to 99%, failing to satisfy customized demands for high-end injectable-grade products. The client’s R&D progress was severely delayed, and they urgently entrusted HiSiaddi to complete process customization, sample trial production, testing verification and mass production launch within 30 days.
1. Process Bottleneck: Conventional fermentation and crystallization processes cannot raise purity to 99.5%, and impurities (especially D-Tryptophan) cannot be controlled below 0.05%;
2. Uncontrollable Crystal Form: General products adopt mixed crystal forms (α+β) with poor fluidity and slow dissolution rate, incompatible with rapid sterile dissolution for injectable production;
3. Lack of Sterile Packaging Capabilities: Most manufacturers only provide ordinary woven bags or single-layer aluminum foil bags without qualifications and equipment for sterile nitrogen-filled vacuum packaging;
4. Slow Technical Response: Manufacturers lack experience in high-end pharmaceutical customization, unable to rapidly adjust processes, coordinate testing or provide English technical documents;
5. High Compliance Risks: Customized products require full testing under both EP and USP standards, while conventional manufacturers lack sufficient testing capacity and cannot issue English COAs and traceability reports meeting regulatory standards.
Based on industry resources and technical research, HiSiaddi identified Jiangsu Caiwei Biotechnology Co., Ltd. — the only domestic L-Tryptophan producer integrating enzymatic hydrolysis, membrane separation and low-temperature recrystallization processes. The enterprise owns full-chain capabilities for high-purity pharmaceutical customization, crystal form regulation, sterile packaging and EP/USP testing, and its products comply with EP and USP standards. It has served multiple top European pharmaceutical enterprises.
HiSiaddi collaborated with Caiwei’s technical team to conduct special process optimization tailored to client demands:
1. Ultra-high Purity Purification: Secondary membrane separation (nanofiltration + ultrafiltration) was added on the basis of conventional fermentation to accurately remove macromolecular impurities and fermentation by-products. Low-temperature gradient recrystallization (4℃-10℃) was adopted to inhibit D-Tryptophan generation, boosting purity to 99.6%, controlling single impurities at 0.03%, and reducing endotoxin to 0.08EU/mg, all exceeding client requirements;
2. Targeted Preparation of α-Type Crystals: The crystallization pH value (5.8-6.2) and stirring speed were adjusted, and food-grade crystal seeds were added for induction to achieve 100% α-type acicular crystals. Its fluidity (angle of repose: 32°) and water solubility (completely dissolved within 10s at 25℃) fully satisfy injectable production standards;
3. Sterile Process Control: The entire production is carried out in Class 10,000 clean workshops with sterile isolation in crystallization, drying and packaging links to avoid secondary contamination.
1. Sterile Packaging Customization: The factory’s pharmaceutical-grade sterile packaging line was activated, adopting double-layer aluminum foil composite film (inner sterile PE layer + outer aluminum foil layer) for vacuum nitrogen-filled packaging with 5kg per bag. Batch number, purity, crystal form, sterile status and validity period are printed on each bag to comply with EU sterile pharmaceutical packaging standards;
2. Exclusive Traceability System: A fully English traceability template was customized for the client, including:
1. Fermentation strain certificate (Streptomyces sp., non-GMO);
2. Fermentation process parameters (temperature, pH, duration);
3. Membrane separation and recrystallization process records;
4. Full-item test reports per batch (EP/USP standards, covering purity, impurities, endotoxin and crystal form);
5. Production equipment cleaning verification reports.
1. Small-batch Sample Production: 3kg trial samples were produced in 3 batches of 1kg each in accordance with customized processes;
2. Authoritative Testing: Samples were sent to SGS European laboratory for full-item testing per EP 11.0 and USP 45-NF 40 standards, with English test reports issued:
1. Purity: 99.6% (pass, ≥99.5%);
2. Single impurity: 0.03% (pass, ≤0.05%);
3. Endotoxin: 0.08EU/mg (pass, <0.1EU/mg);
4. Crystal form: 100% α-type acicular crystal;
5. Microorganisms: sterile, free of pathogenic bacteria.
3. Client Internal Verification: After samples were delivered to Germany, the client’s R&D team conducted dissolution, sterility and formula compatibility tests. All results passed, with no peculiar odor, no precipitation and no negative impact on drug activity.
1. Flexible Production Scheduling: Priority production was arranged at Caiwei, launching a 500L customized production line with HiSiaddi technical staff stationed on-site for full-process supervision in strict accordance with small-batch process parameters;
2. Batch Quality Control: Sampling and testing were conducted every 2 hours to ensure stable purity, impurity content, crystal form and endotoxin levels;
3. Compliance Documents: English COAs, SGS test reports, traceability reports, sterility certificates, non-GMO statements and REACH registration documents were prepared in advance;
4. Logistics Delivery: Temperature-controlled cold chain transportation (2℃-8℃) with real-time temperature monitoring was adopted. Goods were delivered to Germany on schedule without damage or contamination.
1. All customized indicators fully met standards
1. Purity: 99.6%, 0.1% higher than client’s requirement;
2. Single impurity: 0.03%, 0.02% lower than the limit;
3. Endotoxin: 0.08EU/mg, 0.02EU/mg below the threshold;
4. Crystal form: 100% α-type acicular crystal with fluidity and solubility perfectly matching injectable production;
5. Packaging: Sterile nitrogen-filled aluminum foil bags complying with EU standards;
6. Testing: Full-item compliance with EP and USP standards with complete and compliant documents.
2. Client R&D Breakthrough & Smooth New Product Progress The customized L-Tryptophan was successfully applied to the client’s new generation of 5-hydroxytryptamine precursor injectable drugs. Formula stability and drug absorption rate increased by 25% with no allergic reactions, and the product has entered pre-clinical research, advancing the client’s R&D timeline by 2 months.
3. Establishment of Long-Term Customized Cooperation The client designated HiSiaddi as its exclusive Chinese supplier for customized L-Tryptophan. The first batch order of 500kg was placed, and all 2 tons of annual high-end customized L-Tryptophan demand will be supplied by HiSiaddi, covering full-link services including process optimization, production supervision, quality control, compliance documentation and logistics delivery.
Client Feedback: “HiSiaddi not only helped us break through technical bottlenecks in high-purity L-Tryptophan customization, but also provided exclusive one-stop services from process R&D to delivery. Professional, efficient and reliable, they fully meet our stringent requirements for high-end injectables and are the most trustworthy customization partner for our entry into the Chinese market!”
When overseas mid-to-high-end clients purchase customized high-pharmaceutical-grade L-Tryptophan, their core pain points lie in “purity process bottlenecks, uncontrollable crystal forms, lack of sterile packaging, slow technical response and difficulties in compliance testing”. Conventional manufacturers only supply standard general products and cannot satisfy customized demands for ultra-high purity, ultra-low impurities, special crystal forms, sterile packaging and exclusive traceability required by high-end injectables and medical food, which will easily delay client R&D projects.
HiSiaddi’s core value lies in “in-depth amino acid industry resources + proficient high-end pharmaceutical customization processes + full-link technical service capacity”: we accurately match manufacturers with customization capabilities, jointly conduct molecular-level process optimization and targeted crystal form regulation, customize sterile packaging and exclusive traceability systems, and conduct testing verification in strict accordance with international pharmacopoeia standards. We deliver full-process solutions from demand confirmation to mass delivery within 30 days, helping clients break technical barriers, accelerate R&D progress, consolidate high-end market positioning and avoid customization risks.
Please contact HiSiaddi customer service if you require more customized service solutions.
+86-13120989737 
info@hisiaddi.com 
English
